At the ACMG meeting, a Children's Hospital of Philadelphia researcher described finding relatively high rates of hereditary cancer variants in tumor sequence data.
With mutation, expression, and epigenetic features from hundreds of medulloblastoma tumors, researchers characterized key features of brain tumor subtypes.
The study showed that targeted sequencing was feasible, identified many clinically relevant alterations, and directed effective targeted therapy in several cases.
